Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239967 · ClinicalTrials.gov registry record · Phase 3
An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 803
- Enrollment target
NCT00239967 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 803 participants.
The verdict
NCT00239967, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 803 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600 kcal deficit per day) in abdominally obese patients with atherogenic dyslipidemia (low HDL and/or high TG plasma levels). The secondary objectives are to evaluate specific metabolic parameters, visceral fat (in selected sites), safety and tolerability of rimonabant 20 mg.
Interventions
- DRUG Placebo
- DRUG Rimonabant (SR141716)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239967
The ClinicalTrials.gov registry entry for NCT00239967 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 803 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00239967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00239967 about?
NCT00239967 is a clinical study titled "An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients". The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600 kcal deficit per day) in abdominally obese patients with atherogenic dysl...
What is the current status of trial NCT00239967?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 803 participants. The study started on 2005-05. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00239967?
The interventions under investigation include: Placebo (DRUG), Rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00239967?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.